Chelsie Derman

A study found that higher PM2.5 exposure during the first year after NICU discharge increased asthma risk in children with bronchopulmonary dysplasia by age 5.

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.

A review shows that real-world persistence with asthma biologics depends not only on efficacy, but also on patient perceptions and mental health.

Study finds comparable IgE reductions with heated milk and conventional desensitization, but heated milk linked to higher anaphylaxis risk in children with cow’s milk allergy.

In a new study, children exposed to gestational diabetes showed lower FEV1 and increased odds of current asthma at ages 8–9 years.

Registry data show worse asthma control, more exacerbations, and higher healthcare utilization in patients with severe asthma and a comorbid sleep disorder.

DBV Technologies announced that the phase 3 VITESSE trial on VIASKIN® Peanut patch for peanut-allergic children met its primary endpoint.

FibroGen’s oral HIF-PH inhibitor showed improved transfusion independence in high–high-transfusion-burden MDS patients in a post hoc phase 3 MATTERHORN analysis.

Berotralstat (ORLADEYO) oral pellets become the first FDA-approved therapy specifically designed to prevent HAE attacks in children aged 2 – 11 years.

A 20-year population study found unilateral adrenalectomy raises long-term risks of CKD and gout in primary aldosteronism.

A review in Wichita, Kansas, shows asthma-related emergency visits spike during storms, underscoring the importance of weather-based asthma action plans for at-risk patients.

Study shows house dust mite SLIT therapy is safe in children with allergic asthma, though COVID-19–related drops in exacerbations impacted the primary endpoint.

Teva submitted an NDA on olanzapine extended-release injectable suspension (TEV-‘749) for adult schizophrenia to the FDA.

Following its 2025 FDA approval, lumateperone 42 mg demonstrated meaningful reductions in MADRS and CGI-S scores in adults with major depressive disorder.

Oral bradykinin B2 receptor antagonist resolved HAE attacks in under 90 minutes, with most patients needing only a single dose and no rescue medication.

A survey found many obstetric physicians rarely refer pregnant patients for allergy or immunology care, citing knowledge gaps and long wait times.

This month in review highlights November’s biggest psychiatry stories, including FDA moves, phase 4 findings, and new data on digital mental health tools.

This month in review spotlights 5 top allergy headlines published in November, including late-breaking data at ACAAI 2025.

The oral C5aR inhibitor produced durable responses across multiple doses in an 8-week trial, prompting InflaRx to move forward with phase 2b development.

Board-certified allergist shares how clinicians can better recognize and prevent atopic dermatitis in patients with skin of color, addressing pigmentation.

A quick guide for clinicians on epinephrine dosing, optimal observation periods, and the role of tryptase and other labs in anaphylaxis care.

A study showed that users readily adopt mental health apps, but adherence and follow-up completion lag; reminders and human support improve engagement.

Otsuka Pharmaceuticals seeks FDA approval for centanafadine, a novel ADHD treatment, showing significant efficacy in pivotal clinical trials.

Phase 4 double-blind data reveal improved remission, but no significant difference in response between perospirone and placebo.

Two large cohort studies found greater infection and implant-related risks in patients with atopic skin conditions after major surgeries.

New findings reveal the Viaskin Peanut Patch effectively builds peanut tolerance in over 70% of toddlers, offering hope for allergy management.

Study finds eczema onset at 4–6 months, greater severity, and longer duration linked to lower odds of outgrowing food allergies in children.

Late-breaking REZOLVE-AD data show rezpegaldesleukin 24 μg/kg improves skin and asthma, supporting its potential in moderate-to-severe atopic dermatitis.

Here, we spotlighted 4 late-breaker studies featured in our ACAAI 2025 coverage, along with 2 phase 3 trials.

In this Q&A, Soong discusses phase 2 results on povorcitinib, a JAK1 inhibitor that provides rapid relief from chronic spontaneous urticaria symptoms.